Genelux (GNLX) Long-Term Deferred Tax (2023 - 2025)
Genelux (GNLX) posted Long-Term Deferred Tax of $93.7 million for Q4 2025, up 419514.87% on a QoQ basis from $22330.0 in Q4 2023.
Powered by 
Analysis
Genelux (GNLX) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Genelux has reported Long-Term Deferred Tax for 2 years, with the latest figure at $93.7 million in Q4 2025.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $93.7 million in Q4 2025; TTM through Dec 2025 was $93.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $93.7 million, changed N/A from the prior year.
- Long-Term Deferred Tax was $93.7 million for Q4 2025 at Genelux, up from $22330.0 in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $93.7 million in Q4 2025, with the low at $22330.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - |